Research News
View articles by month and year
1–6 of 6 articles
-
Perjeta Improves Overall Survival in HER2-Positive, Metastatic Disease
More results from the CLEOPATRA study show that women who got Perjeta, Herceptin, and Taxotere had better overall survival than women who got only Herceptin and Taxotere.
-
FDA Approves Perjeta for Metastatic, HER2-Positive Disease
The FDA has approved using Perjeta (chemical name: pertuzumab) in combination with Herceptin and Taxotere to treat HER2-positive, metastatic breast cancer that hasn't been treated with either Herceptin or chemotherapy yet.
-
Experimental Omnitarg May Help Treat Metastatic, HER2-Positive Disease
Research suggests that adding the experimental medicine Omnitarg to a combination of Herceptin and Taxotere slows the growth of metastatic HER2-positive breast cancer more than Herceptin and Taxotere alone.
-
Experimental Combo of Herceptin and Omnitarg Helps Treat Advanced-Stage HER2-Postitive Disease
Treatment before surgery with Herceptin and Omnitarg alone or with Taxotere benefited women diagnosed with locally-advanced or inflammatory HER2-positive breast cancer.
-
HER2-Positive Breast Cancer May Respond to Experimental Treatments
Early results from a very early study suggests that some advanced-stage, HER2-positive breast cancers that have stopped responding to Herceptin may respond to the experimental treatment T-DM1.
-
Experimental Regimen May Work Against Treatment-Resistant Breast Cancer
A combination of two experimental targeted therapies shows promise in treating advanced-stage HER2-positive breast cancer.
1–6 of 6 articles
